Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

25%(1 trials)

Terminated

1(20%)

Phase Distribution

Ph early_phase_1

40%

Ph phase_2

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Early Phase 1First-in-human

2(66.7%)

Phase 2Efficacy & side effects

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Detailed Status

Completed4

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 2

Trials by Phase

Early Phase 12 (66.7%)

Phase 21 (33.3%)

Trials by Status

completed480%

terminated120%

Recent Activity

0 active trials

Showing 5 of 5

completed

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

NCT03236311

completedearly_phase_1

An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients

NCT02669563

Clinical Trials (5)

Showing 5 of 5 trials

NCT03648905

Clinical Laboratory Evaluation of Chronic Autonomic Failure

Completed

NCT05625490Early Phase 1

Myocardial Perfusion Imaging Galmydar Rest/Stress

Completed

NCT00775853

Biomarkers of Risk of Parkinson Disease

Completed

NCT03236311Phase 2

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

Terminated

NCT02669563Early Phase 1

An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5